Company Announcement no. 29/2007
To: OMX Nordic Exchange Hørsholm, Denmark, 27 November 2007
LifeCycle Pharma Announces Financial Results for the first 9 Months of 2007
Hørsholm, Denmark, 27 November 2007; LifeCycle Pharma A/S (OMX: LCP), an
emerging specialty pharmaceutical company, today announced financial results for
the nine months ended 30 September 2007. The reported results are as follows:
* LifeCycle Pharma has already achieved most of the clinical and regulatory
milestones for 2007 and at the same time been able to demonstrate significant
savings. Therefore, the company now improves its financial guidance for the year
and now expects a cash position at the end of 2007 in the range of DKK 315 to
340 million compared to previously expected DKK 215 to 240 million.
* LifeCycle Pharma has reported an operating loss for the first nine months of
2007 of DKK 98.0 million and a net loss of DKK 87.9 million.
* At 30 September 2007, LifeCycle Pharma had cash and cash equivalents of DKK
397.4 million.
* During the third quarter of 2007, LifeCycle Pharma initiated a US Phase II
clinical trial program with LCP-AtorFen for the treatment of mixed dyslipidemia
and received US FDA approval for its LCP-FenoChol product for the treatment of
hyperlipidemia and hypertriglyceridemia.
* Finally, LCP-Tacro has in a number of clinical trials demonstrated a best in
class profile when compared to both Prograf® and Advagraf®, the only two other
tacrolimus products currently marketed. Clinical results show that LCP-Tacro
(once daily) has higher bioavailability, better pharmacokinetics, a flatter
product profile, and potential for administration at lower daily doses.
Conference Call
LifeCycle Pharma's management will hold a conference call to discuss the results
for the nine months ended 30 September 2007 on
Wednesday 28 November 2007 at 15:00 CET (14:00 GMT / 9:00 a.m. ET)
To access the live telephonic broadcast, callers may dial the following numbers:
Denmark: 80 88 49 65
US: (800) 299-7635 (toll-free)
Others: +1 617 786 2901
Confirmation code for all participants: 699 390 60
Grant of Warrants
Also today, the board of directors decided to issue 58,500 warrants to new
employees of the company and the company's subsidiary. No members of the
company's management were granted warrants. Of the 58,500 warrants, 30,000
warrants are allocated to key employees and 28,500 warrants are allocated to
other employees. Each warrant entitles the holder to subscribe one share of
nominal DKK 1 in the company against cash contribution equal to the closing
price of the company's shares at the OMX Nordic Exchange on 28 November 2007, to
ensure that the exercise price reflects the fair market price per share
following the disclosure of the interim financial report for the first nine
months of 2007.
By application of the Black-Scholes formula, the market value of the warrant
program can be calculated as DKK 13.21 per warrant assuming an exercise price of
DKK 40.00, equal to the closing price of the company's share at the OMX Nordic
Exchange on 27 November 2007, based on an interest rate of 4.28% and a
volatility of the company's shares set to 35%. The aim of the issue is to give
an incentive to the recipients to work towards a positive development in the
company's business and by extension, an increase in the market price of the
company's shares. The warrants vest by 1/48th per month of
employment/affiliation after the date of grant. The exercise periods are
determined as 21 days from the company's announcements of its preliminary annual
report and the interim financial report for the first half of a year,
respectively. The first exercise period is 21 days after publication of the
preliminary annual report for 2008 and the last exercise period is 21 days from
publication of the interim financial report for the first half of 2014. The
board of directors has issued the warrants by partly exercising the
authorization contained in Article 8 of the company's articles of association
according to which the board of directors - for a period ending on 23 April 2012
- on one or more occasions may issue up to 326,619 warrants each conferring a
right to subscribe 1 share of nominally DKK 1 each in Lifecycle Pharma without
preemptive subscription rights for the shareholders. After the issue of the
58,500 warrants, 268,119 warrants remain available for issue under the
authorization and the total number of warrants outstanding in the company is
4,076,142 warrants.
About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceuticals company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop drugs
with enhanced absorption and thereby increased bioavailability. Currently, the
Company has a diversified near- and medium-term pipeline, including a product
ready for US commercialization, four product candidates in clinical trials and
four in preclinical stages of development. LCP is listed on the OMX Nordic
Exchange under the trading symbol (OMX: LCP). For further information, please
visit www.lcpharma.com.
Contact:
Michael Wolff Jensen
EVP and CFO
+45 4074-6244
MWJ@lcpharma.com
---oo0oo---
LifeCycle Pharma Announces Financial Results for the first 9 Months of 2007
| Quelle: Veloxis Pharmaceuticals A/S